Safety, Tolerability and Pharmacokinetic Profile of M108 Monoclonal Antibody in Patients With Advanced Unresectable Solid Tumors in China

NCT04894825 · clinicaltrials.gov ↗

PHASE1

Phase

UNKNOWN

Status

152

Enrollment

INDUSTRY

Sponsor class

Conditions

Advanced Unresectable Solid Tumors

Interventions

DRUG: M108
DRUG: M108

Sponsor

FutureGen Biopharmaceutical (Beijing) Co., Ltd